Media stories about Celgene (NASDAQ:CELG) have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by monitoring more than 6,000 blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Celgene earned a news sentiment score of -1.83 on their scale. InfoTrie also assigned media headlines about the biopharmaceutical company an news buzz score of 3 out of 10, indicating that recent media coverage is unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media stories that may have effected Celgene’s ranking:
A number of equities research analysts have commented on CELG shares. Morgan Stanley reduced their price target on shares of Celgene from $93.00 to $88.00 and set an “equal weight” rating for the company in a report on Wednesday, December 19th. Leerink Swann set a $112.00 price target on shares of Celgene and gave the stock a “hold” rating in a report on Friday, October 26th. BidaskClub upgraded shares of Celgene from a “strong sell” rating to a “sell” rating in a report on Friday, January 4th. ValuEngine upgraded shares of Celgene from a “strong sell” rating to a “sell” rating in a report on Friday, January 4th. Finally, Canaccord Genuity cut shares of Celgene from a “buy” rating to a “hold” rating in a report on Thursday, January 3rd. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $111.78.
CELG opened at $87.51 on Thursday. The company has a debt-to-equity ratio of 4.06, a quick ratio of 1.99 and a current ratio of 2.13. Celgene has a fifty-two week low of $58.59 and a fifty-two week high of $107.29. The stock has a market cap of $59.37 billion, a P/E ratio of 12.79, a PEG ratio of 0.43 and a beta of 1.44.
Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share for the quarter, beating analysts’ consensus estimates of $2.02 by $0.27. The company had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.83 billion. Celgene had a net margin of 19.64% and a return on equity of 108.76%. Equities research analysts predict that Celgene will post 7.45 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2019/01/10/celgene-celg-receives-coverage-optimism-rating-of-1-83.html.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
See Also: Certificate of Deposit (CD)
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.